XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration and Other Agreements - Incyte Corporation (Details)
 3 Months Ended 6 Months Ended 7 Months Ended 9 Months Ended 24 Months Ended 54 Months Ended
Jun. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jul. 31, 2022
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
performanceObligation
Jun. 30, 2022
USD ($)
Jul. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaboration And Other Agreements [Line Items]                          
Revenues $ 26,007,000   $ 30,757,000 $ 37,108,000 $ 47,638,000                
Deferred revenue, current 11,565,000     11,565,000           $ 11,565,000   $ 20,646,000  
Deferred revenue, net of current portion 6,163,000     6,163,000           6,163,000   0  
Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment               $ 150,000,000          
Potential development and regulatory milestone payments under agreement                 $ 435,000,000        
Potential commercial milestone payments under agreement                 $ 330,000,000        
Development and regulatory milestones recognized         15,000,000         70,000,000      
Number of performance obligations | performanceObligation                 2        
Collaborative agreement transaction price                 $ 154,000,000        
Variable consideration recognized                 $ 4,000,000        
Incyte Corporation | Incyte MGA012 Agreement | Subsequent Event                          
Collaboration And Other Agreements [Line Items]                          
Two Additional Incyte License Agreement Milestone                     $ 30,000,000    
I-Mab | I-Mab Biopharma Collaboration and License Agreement                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment             $ 15,000,000            
Potential development and regulatory milestone payments under agreement                         $ 135,000,000
Development and regulatory milestones recognized   $ 5,000,000   5,000,000                  
Revenues 600,000   1,900,000 700,000 2,500,000                
Deferred revenue 3,800,000     3,800,000           3,800,000   $ 4,500,000  
Minimum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               15.00%          
Maximum | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)               24.00%          
Maximum | I-Mab | I-Mab Biopharma Collaboration and License Agreement                          
Collaboration And Other Agreements [Line Items]                          
Potential proceeds from royalties (percent)             20.00%            
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement                          
Collaboration And Other Agreements [Line Items]                          
Revenues               $ 150,000,000          
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities                          
Collaboration And Other Agreements [Line Items]                          
Revenues 0   5,000,000 0                  
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Clinical Services                          
Collaboration And Other Agreements [Line Items]                          
Revenues 200,000   700,000 500,000 800,000                
Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Supply Agreement                          
Collaboration And Other Agreements [Line Items]                          
Revenues 300,000   $ 2,800,000 300,000 $ 5,900,000                
RevenuesFromCMOAgreementsMember | Incyte Corporation                          
Collaboration And Other Agreements [Line Items]                          
Revenues       4,000,000                  
Deferred revenue 9,500,000     9,500,000           9,500,000      
Deferred revenue, current 3,300,000     3,300,000           3,300,000      
Deferred revenue, net of current portion 6,200,000     6,200,000           6,200,000      
Annual Fixed Payments $ 14,400,000     $ 14,400,000           $ 14,400,000      
RevenuesFromCMOAgreementsMember | Incyte Corporation | Subsequent Event                          
Collaboration And Other Agreements [Line Items]                          
Non-refundable upfront payment           $ 10,000,000